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ABSTRACT 
Pharmaceutical Process Validation emphasizes on process design elements and  maintaining  process  
control  during commercialization and communicate that process validation is an ongoing program and 
align process validation activities with product lifecycle. According to GMP validation studies are 
essential part of GMP these are required to be done as per predefined protocols, the minimum that 
should be validated include process, testing and cleaning as a result such control procedure stablish to 
monitor the output and validation of manufacturing processes that may be responsible for variability of 
drug product. The validation study provide the accuracy, sensitivity, specificity and reproducibility of 
the test methods employed by the firms, shall be established and documented. Thus the validation is an 
essential part of the quality assurance.  
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Introduction 
Pharmaceutical Process Validation is the  most 
important and recognized parameters of 
cGMPs. The concept of validation  has  
expanded through the years  to embrace a 
wide range of activities from analytical 
methods used for the quality control of drug 
substances and drug products to computerized 
systems for clinical trials, labelling or  process  
control.  Validation isfounded on, but not 
prescribed by regulatory requirements and is 
best viewed as an important and integral part 
of cGMP.[1]  According  to  FDA, assurance 
of product quality is derived  from  careful  
and systemic attention to a number of 
importance factors, including: selection of 
quality process through in-process and end-
product testing.[2] The concept of validation 
was first proposed by two Food and Drug 
Administration (FDA) officials, Ted Byers 
and Bud Loftus, in the mid 1970s in order to 
improve the quality of pharmaceuticals.[3] 
 
Need of Pharmaceutical Validation  
Validation is an integral part of quality 
assurance; it involves the systematic study of 
systems, facilities and processes aimed at 
determining whether they perform their 
intended functions adequately and consistently 
as specified. A validated process is one which 
has been demonstrated to provide a high 
degree of assurance that uniform batches will 
be produced that meet the required 
specifications and has therefore been formally 
approved. Validation in itself does not improve 
processes but confirms that the processes have 
been properly developed and are under control 
[4].  
Major Phases in Validation  
The activities relating to validation studies 
may be classified into three:  
Phase 1: This is the Pre-validation 
Qualification Phase which covers all activities 
relating to product research and development, 
formulation pilot batch studies, scale-up 
reliably. Process validation is required, in both 
general and specific terms, by the CGMP 
regulations in parts 210 and 211. The 
foundation for process validation is provided 
in § 211.100(a), which states that “[t] here 
shall be written procedures for production and 
process control designed to assure that the drug 
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products have the identity, strength, quality, 
and purity they purport or are represented to 
possess...” (emphasis added). This regulation 
requires manufacturers to design a process, 
including operations and controls, which 
results in a product meeting these attributes 
studies, transfer of technology to commercial 
scale batches, establishing stability conditions 
and storage, and handling of in-process and 
finished dosage forms, equipment 
qualification, installation qualification, master 
production document, operational qualification 
and process capacity. 
Phase 2: This is the Process Validation Phase. 
It is designed to verify that all established 
limits of the critical process parameter are 
valid and that satisfactory products can be 
produced even under the worst conditions.  
Phase 3: Known as the Validation 
Maintenance Phase, it requires frequent review 
of all process related documents, including 
validation of audit reports, to assure that there 
have been no changes, deviations, failures and 
modifications to the production process and 
that all standard operating procedures (SOPs), 
including change control procedures, have 
been followed. At this stage, the validation 
team comprising of individuals representing all 
major departments also assures that there have 
been no changes/deviations that should have 
resulted in requalification and revalidation. A 
careful design and validation of systems and 
process controls can establish a high degree of 
confidence that all lots or batches produced 
will meet their intended specifications. It is 
assumed that throughout manufacturing and 
control, operations are conducted in 
accordance with the principle of good 
manufacturing practice (GMP) both in general 
and in specific reference to sterile product 
manufacture[5,6].
Process Validation  
Process validation is the means of ensuring and 
providing documentary evidence that processes 
(within their specified design is beneficial to 
the manufacturer in many ways  
 1. It deepens the understanding of processes; 
decreases the risk of preventing problems and 
thus assures the smooth running of the process.  
2. It decreases the risk of defect costs.  
3. It decreases the risk of regulatory non- 
compliance.  
4. A fully validated process may require less 
in-process controls and end- product testing.  
Validation should thus be considered in the 
following situations:  
1. Totally new process;  
2. New equipment;  
3. Process and equipment which have been 
altered to suit changing priorities; and  
4. Process where the end-product test is poor 
and an unreliable indicator of product quality. 
 
When any new manufacturing formula or 
method of preparation is adopted, steps should 
be taken to demonstrate its suitability for 
routine processing. The defined process should 
be shown to yield a product consistent with the 
required quality. In this phase, the extent to 
which deviations from chosen parameters can 
influence product quality should also be 
evaluated. When certain processes or products 
have been validated during the development 
stage, it is not always necessary to revalidate 
the whole process or product if similar 
equipment is used or similar products have 
been produced, provided that the final product 
conforms to the in-process controls and final 
product specification. There should be a clear 
distinction between in-process control and 
validation. In production, tests are performed 
each time on a batch to batch basis using 
specifications and methods devised during the 
development phase. The objective is to 
monitor the process continuously.Parameters 
are capable of repeatedly and reliably 
producing a finished product of the required 
quality. It would normally be expected that 
process validation be completed prior to the 
release of the finished product for sale 
(prospective validation). Where this is not 
possible, it may be necessary to validate 
processes during routine production 
(concurrent validation). Processes, which have 
been in use for some time without any 
significant changes, may also be validated 
according to an approved protocol 
(retrospective validation) [7-15] . 
Pre-requisites for Process Validation  
Before process validation can be started, 
manufacturing equipment and control 
instruments as well as the formulation must be 
qualified. The information on a pharmaceutical 
product should be studied in detail and 
qualified at the development stage, i.e., before 
an application for marketing authorization is 
submitted. This involves studies on the 
compatibility of active ingredients and 
recipients, and of final drug product and 
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packaging materials, stability studies, etc. 
Other aspects of manufacture must be 
validated including critical services (water, air, 
nitrogen, power supply, etc.) and supporting 
operations such as equipment cleaning and 
sanitation of premises. Proper training and 
motivation of personnel are prerequisites to 
successful validation. 
The Pharmaceutical Process Equipment The 
key idea of validation is to provide a high level 
of documented evidence that the equipment 
and the process conform to a written standard. 
The level (or depth) is dictated by the 
complexity of the system or equipment. The 
validation package must provide the necessary 
information and test procedures required to 
provide that the system and process meet 
specified requirements[14,15].  
Validation of pharmaceutical process 
equipment involves the following: 
Installation Qualification (IQ) 
This ensures that all major processing and 
packaging equipment, and ancillary systems 
are in conformity with installation 
specification, equipment manuals schematics 
and engineering drawing. It verifies that the 
equipment has been installed in accordance 
with manufacturers recommendation in a 
proper manner and placed in an environment 
suitable for its intended purpose.  
Operational Qualification (OQ): This is done 
to provide a high degree of assurance that the 
equipment functions as intended. Operational 
qualification should be conducted in two 
stages:  
1. Component Operational Qualification, of 
which calibration can be considered a large 
part. 
2. System Operational Qualification to 
determine if the entire system operates as an 
integrated whole.  
 
Process Performance Qualification (PQ): 
  
This verifies that the system is repeatable and 
is consistently producing a quality product . 
These exercises assure, through appropriate 
performance lists and related documen- tation, 
that equipment, ancillary systems and sub-
systems have been commissioned correctly. 
The end results are that all future operations 
will be reliable and within prescribed 
operational limits. At various stages in a 
validation exercise there are needs for 
protocols, documentation, procedures, 
specifications and acceptance criteria for test 
results. All these need to be reviewed, checked 
and authorized. It would be expected that 
representatives from the professional 
disciplines, e.g., engineering, research and 
development, manufacturing, quality control 
and quality assurance are actively involved in 
these undertakings with the final authorization 
given by a validation team or the quality 
assurance representative[16]  
Expert Evaluation  
This is an evaluation of the entire study against 
the protocol requirements as outlined above. It 
should be prepared and the conclusion drawn 
at each stage stated. The final conclusions 
should reflect whether the protocol 
requirements were met. The evaluation should 
include an assessment of the planned 
calibration and maintenance programmes for 
the equipment and instrumentation to maintain 
the validated conditions. In addition, all 
process monitoring and control procedures 
required to routinely ensure that the validated 
conditions are maintained should be reported. 
The evaluation should be signed by authorized 
officers of the organization who were members 
of the team establishing the protocol and who 
have appropriate expertise in the area assigned 
to them. Overall approval of the study should 
be authorized by the head of the validation 
team and the head of the quality control 
department [17] 
Validation Report  
A written report should be available after 
completion of the validation. If found 
acceptable, It should be approved and 
authorized (signed and dated). The report 
should include at least the following: 
 Title and objective of study;  
 Reference to protocol;  
 Details of material;  
 Equipment;  
 Programmes and cycles used;  
 Details of procedures and test methods;  
 Results (compared with acceptance 
criteria); and  
 Recommendations on the limit and 
criteria to be applied on future basis. 
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It is necessary, before approval of a new drug, 
that an accurate and reliable assessment for its 
effectiveness and safety for the intended 
indication and target patient population is 
demonstrated. Pharmaceutical Process 
Validation is the  most important and 
recognized parameters of cGMP. It is 
necessary, before approval of a new drug, that 
an accurate and reliable assessment for its  
effectiveness and safety for the intended 
indication and target patient population is 
demonstrated. Generally, pharmaceutical 
validation and process control provide a 
certain assurance of batch uniformity and 
integrity of the product manufactured. 
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